Research on monoclonal antibody OX26 modified salvianolic acid B/baicalin nanostructured lipid carriers / 中草药

ABSTRACT

Objective To prepare, characterize, and study cellular uptake of transferrin receptor monoclonal antibody OX26 modified nanostructured lipid carrier loaded with salvianolic acid B and baicalin (Sal B/BA-NLC). Methods Sal B/BA-NLC was prepared by emulsification-solvent evaporation method. OX26 was thiolated with 2-iminothiolane hydrochloride and then conjugated to the surface of Sal B/BA-NLC. The morphology, particle size, Zeta potential, and encapsulation efficiency (EE) were evaluated for the physicochemical properties, and OX26 modified Sal B/BA-NLC was verified by differential scanning calorimetry (DSC) and nuclear magnetic resonance spectroscopy (NMR). Coumarin-6 (C6) was used as the fluorescent probe instead of baicalin and salvianolic acid B to prepare the formulations in cellular uptake study. The cellular uptake study was conducted by brain microvascular endothelial cells bEnd.3 using high content cell imaging analysis system. Results The prepared OX26 modified Sal B/BA-NLC had particle size of (27.50 ± 3.37) nm, PDI of 0.39 ± 0.04, and Zeta potential of (-7.06 ± 1.85) mV. The DSC and NMR results indicated that the drug was encapsulated in the nanostructured lipid carrier in an amorphous form. The results of cell uptake showed that the fluorescence intensities of the three solutions in bEnd.3 cells were OX26-C6-NLC > C6-NLC > C6-SL. Conclusion The prepared OX26 modified Sal B/BA-NLC has smaller particle size, uniform distribution, and high EE. The OX26-modified NLC group had a higher intake than the solution group and the unmodified NLC group.